We are Sorry, This Page doesn't Exist

Incon Co., a publicly traded South Korean biotech investor, has given Weston-based Variant Pharmaceuticals $10 million in financing in exchange for equity ownership. The funding will be used to develop VAR 200 for the treatment of rare kidney disease .....»»

The experimental treatment slowed the disease, but not enough to meet investors' high expectations.....»»

A newly launched biotech company has secured $65 million in financing as it seeks to develop the first-ever treatment for a disorder that its co-founder described as “the life being squeezed out of the liver.” Cambridge-based Akero Therapeutics is fo.....»»

This finding could pave the wave for Alzheimer's treatment and biomarkers for early diagnosis......»»

The two IPOs on this week's calendar include one tech unicorn and a biotech working on a treatment from Alzheimer disease......»»

STOCKHOLM, Feb. 14, 2019 /PRNewswire/ -- BioArctic's partner Eisai will initiate BAN2401 confirmatory Phase 3-study in early Alzheimer's disease. AbbVie in-licensed the Parkinson po.....»»

Stocks that moved substantially or traded heavily on Tuesday: Gilead Sciences Inc., down $2.22 to $65.40 A potential liver disease under development by the biotechnology company failed to meet its treatment goal in a key study......»»

In stealth mode, GABAeron is one of a growing number of companies zeroing in on new ways to stall, stop or cure Alzheimer's disease......»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

The show is set to premiere in the fall. Goop is getting the Netflix treatment. According to Variety, the lifestyle and wellness brand founded by actress Gwyneth Paltrow in 2008 is partnering with Netflix to develop a new docus.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 29) read more.....»»

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The P.....»»

Jeff J Mitchell/Getty Images A new study found a .....»»

Non-alcoholic fatty liver disease, or NAFLD, is a disorder resulting from accumulation o.....»»

In a small lab in Jackson Hole, Wyo., 65-year-old Paul Cox believes he’s closing in on a treatment that might prevent Alzheimer’s disease. And ALS. And a host of other .....»»

Omeros Corporation (NASDAQ: OMER) shares are seeing buying interest Thursday following a clinical update on its lead human monoclonal antibody OMS721, which is being evaluated for IgA nephropathy. read more.....»»

Ultragenyx Pharma shares made a handy gain to close out the week after the company announced positive results from its midstage trial for the treatment of glycogen storage disease type Ia......»»

Eric Gaillard/Reut.....»»

On the eve of biotech's biggest conference, Biogen has announced two drug development deals — worth up to almost $500 million combined — targeting Alzheimer's disease and other neurological disorders. Biogen (Nasdaq: BIIB) said Friday that i.....»»